Casdin Capital, LLC
CIK 1534261 · View on SEC EDGAR ↗
- Portfolio value
- $2.0B
- Positions
- 43
- As of
- June 30, 2026
#1,513 of 9,443 by 13F value · top 16.0%
Portfolio value QoQ: +51.3% 13F does not disclose cash
- Top 10 holdings weight
- 77.36%
- Top 25 holdings weight
- 95.89%
- Positions above 1%
- 20
- Effective number of positions
- 9.1
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 8.4% Est. buys $198,606,004 · sells $139,346,363
Median holding: 3.0 quarters Tracked Q4 2024–Q2 2026 · 59.7% still held
- New positions
- 6
- Increased
- 9
- Decreased
- 3
- Closed
- 3
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +31.5% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 98.0% · Options excluded: 0.1%
Sector breakdown
Healthcare
98.0%
Other/Unmapped
2.0%
Full portfolio 43 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. - Common Stock | $482,682,924 | 24.16% | 2,577,333 | $232,037,290 | |||
| RLAY Relay Therapeutics, Inc. - Common Stock | $300,019,340 | 15.02% | 16,035,240 | $156,554,529 | Up ×3 | ||
| WGS GeneDx Holdings Corp. - Class A Common Stock | $254,496,809 | 12.74% | 3,707,164 | $61,376,737 | Up ×1 | ||
| BLFS BioLife Solutions, Inc. - Common Stock | $131,457,200 | 6.58% | 4,655,000 | $17,794,492 | Down ×1 | ||
| ILMN Illumina, Inc. - Common Stock | $93,189,900 | 4.66% | 530,000 | $27,862,100 | |||
| LAB Standard BioTools Inc. - Common Stock | $73,042,478 | 3.66% | 88,783,856 | $-8,576,521 | |||
| GPCR Structure Therapeutics Inc. - American Depositary Shares | $63,062,250 | 3.16% | 1,175,000 | $6,427,250 | |||
| DNLI Denali Therapeutics Inc. - Common Stock | $52,597,400 | 2.63% | 2,045,000 | $17,269,400 | Up ×1 | ||
| NGNE Neurogene Inc. - Common Stock | $48,601,603 | 2.43% | 1,545,361 | $19,967,125 | Up ×2 | ||
| BEAM Beam Therapeutics Inc. - Common Stock | $46,332,000 | 2.32% | 1,350,000 | $14,161,500 | |||
| TXG 10x Genomics, Inc. - Common Stock | $40,257,000 | 2.02% | 1,050,000 | $-8,041,250 | Down ×1 | ||
| SRRK Scholar Rock Holding Corporation - Common Stock | $36,575,000 | 1.83% | 665,000 | $19,369,000 | Up ×2 | ||
| PSNL Personalis, Inc. - Common Stock | $34,170,000 | 1.71% | 2,550,000 | $23,978,000 | Up ×1 | ||
| GRAL GRAIL, Inc. - Common Stock | $32,769,600 | 1.64% | 480,000 | $20,883,200 | Up ×1 | ||
| GH Guardant Health, Inc. - Common Stock | $27,755,550 | 1.39% | 185,000 | $-1,341,000 | Down ×2 | ||
| MAZE Maze Therapeutics, Inc. - Common Stock | $25,180,693 | 1.26% | 843,857 | $2,528,812 | Up ×1 | ||
| HIMS Hims & Hers Health, Inc. Class A Common Stock | $24,269,000 | 1.21% | 700,000 | $9,737,000 | |||
| ALNY Alnylam Pharmaceuticals, Inc. - Common Stock | $22,577,250 | 1.13% | 75,000 | $-2,238,000 | |||
| TSHA Taysha Gene Therapies, Inc. - Common Stock | $22,132,500 | 1.11% | 3,250,000 | $7,605,000 | |||
| AGMB AgomAb Therapeutics NV - ADRs representing one common share. | $20,119,000 | 1.01% | 1,550,000 | $3,859,500 | |||
| SEPN Septerna, Inc. - Common Stock | $18,528,945 | 0.93% | 553,268 | $5,233,915 | |||
| Unknown issuer (CUSIP: 698955101) | $17,672,535 | 0.88% | 645,690 | Up ×1 | |||
| SION Sionna Therapeutics, Inc. - Common Stock | $17,596,000 | 0.88% | 400,000 | Up ×1 | |||
| VCYT Veracyte, Inc. - Common Stock | $16,227,569 | 0.81% | 276,308 | $7,327,688 | |||
| ANL Adlai Nortye Ltd. - American Depositary Shares | $14,375,000 | 0.72% | 1,250,000 | $10,648,850 | Up ×1 | ||
| PRME Prime Medicine, Inc. - Common Stock | $11,686,876 | 0.58% | 3,167,175 | $665,107 | |||
| ABSI Absci Corporation - Common Stock | $11,280,083 | 0.56% | 973,260 | $8,360,303 | |||
| DGX Quest Diagnostics Incorporated Common Stock | $10,597,500 | 0.53% | 50,000 | $798,500 | |||
| SRPT Sarepta Therapeutics, Inc. - Common Stock | $8,445,900 | 0.42% | 470,000 | ||||
| QURE uniQure N.V. - Ordinary Shares | $6,909,000 | 0.35% | 150,000 | Up ×1 | |||
| NTLA Intellia Therapeutics, Inc. - Common Stock | $6,006,600 | 0.30% | 355,000 | $1,455,500 | |||
| MRNA Moderna, Inc. - Common Stock | $5,252,250 | 0.26% | 75,000 | $1,442,250 | |||
| IRON Disc Medicine, Inc. - Common Stock | $4,754,100 | 0.24% | 65,000 | $598,000 | |||
| GLUE Monte Rosa Therapeutics, Inc. - Common Stock | $4,501,539 | 0.23% | 186,014 | $1,441,609 | |||
| IPSC Century Therapeutics, Inc. - Common Stock | $3,009,066 | 0.15% | 1,228,190 | $233,357 | |||
| CTNM Contineum Therapeutics, Inc. - Common stock | $2,431,178 | 0.12% | 148,333 | $493,949 | |||
| BBOT BridgeBio Oncology Therapeutics, Inc. - Common Stock | $2,151,217 | 0.11% | 282,312 | $-375,475 | |||
| EDIT Editas Medicine, Inc. - Common Stock | $1,441,800 | 0.07% | 445,000 | Up ×1 | |||
| PACB Pacific Biosciences of California, Inc. - Common Stock | $1,215,929 | 0.06% | 723,767 | $260,557 | |||
| Unknown issuer (CUSIP: 485925101) | $1,192,500 | 0.06% | 50,000 | Up ×1 | |||
| RXRX Recursion Pharmaceuticals, Inc. - Class A Common Stock | $606,735 | 0.03% | 165,323 | $99,193 | |||
| DNA Ginkgo Bioworks Holdings, Inc. Class A Common Stock | $361,646 | 0.02% | 36,493 | $137,944 | |||
| TNYA Tenaya Therapeutics, Inc. - Common Stock | $267,531 | 0.01% | 361,969 | $16,904 | |||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
| Security | Value | % of portfolio | Streak |
|---|---|---|---|
| RLAY | $300,019,340 | 15.02% | up ×3 |
Biggest new bets
New positions opened this quarter, largest first.
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| RVMD | Price move only | +0 | +$232.0M |
| RLAY | Bought more | +1.6M | +$156.6M |
| WGS | Bought more | +700K | +$61.4M |
| ILMN | Price move only | +0 | +$27.9M |
| PSNL | Bought more | +950K | +$24.0M |
| GRAL | Bought more | +250K | +$20.9M |
| NGNE | Bought more | +125K | +$20.0M |
| SRRK | Bought more | +315K | +$19.4M |
| BLFS | Trimmed | -1.3M | +$17.8M |
| DNLI | Bought more | +205K | +$17.3M |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| RNA | March 31, 2026 | 1,000,000 | $72,130,000 | 1.9% |
| VERV | Sept. 30, 2025 | 4,095,571 | $45,993,262 | No longer tracked |
| BPMC | June 30, 2025 | 326,378 | $28,887,717 | No longer tracked |
| SPRY | March 31, 2026 | 1,600,000 | $18,640,000 | -23.7% |
| CDXS | Sept. 30, 2025 | 7,200,000 | $17,568,000 | -33.8% |
| SRPT | Sept. 30, 2025 | 990,097 | $16,930,659 | -0.6% |
| UNH | March 31, 2026 | 50,000 | $16,505,500 | 45.0% |
| QGEN | June 30, 2026 | 360,000 | $14,414,400 | 14.4% |
| NTLA | June 30, 2025 | 2,000,000 | $14,220,000 | 35.1% |
| TEM | June 30, 2026 | 294,127 | $13,300,423 | 14.6% |
| DXCM | March 31, 2026 | 175,000 | $11,614,750 | 45.0% |
| CI | March 31, 2026 | 40,000 | $11,009,200 | 4.3% |
| ONC | June 30, 2025 | 40,000 | $10,886,800 | 54.0% |
| TSVT | June 30, 2025 | 2,000,000 | $9,880,000 | No longer tracked |
| INCY | March 31, 2026 | 100,000 | $9,877,000 | 36.1% |
| MLTX | June 30, 2026 | 450,000 | $8,388,000 | -15.9% |
| GEHC | June 30, 2025 | 100,000 | $8,071,000 | 1.0% |
| LLY | Sept. 30, 2025 | 8,500 | $6,626,005 | 66.2% |
| FDMT | March 31, 2025 | 1,150,000 | $6,405,500 | 386.2% |
| MRNA | June 30, 2025 | 225,000 | $6,378,750 | 419.2% |
| SNDX | Sept. 30, 2025 | 650,000 | $6,084,000 | 32.2% |
| FTRE | March 31, 2025 | 275,000 | $5,128,750 | 140.9% |
| EXAS | Dec. 31, 2025 | 90,000 | $4,923,900 | No longer tracked |
| LEGN | March 31, 2026 | 215,000 | $4,674,100 | 23.9% |
| VSTM | June 30, 2025 | 600,000 | $3,618,000 | 71.3% |
| AGIO | Sept. 30, 2025 | 100,000 | $3,326,000 | -15.0% |
| SLDB | June 30, 2025 | 775,000 | $2,867,500 | 90.7% |
| TDOC | June 30, 2025 | 300,000 | $2,388,000 | -23.2% |
| DYN | June 30, 2025 | 100,000 | $1,046,000 | 173.3% |
| TNGX | June 30, 2025 | 125,000 | $171,250 | 377.0% |
| KRON | June 30, 2025 | 123,839 | $102,167 | No longer tracked |